Revolution Medicines Inc at JPMorgan Healthcare Conference Transcript
Good morning, I'm Eric Joseph, senior biotech analyst with JPMorgan and our next presenting company is Revolution Medicines. Presenting on behalf of the company is CEO, Mark Goldsmith. There will be a Q&A session after the presentation. Just raise your hand, and we'll get a mic to you. For those tuning in via the webcast, feel free to submit questions via the digital conference book. We can work them in where appropriate. So with that, Mark.
Good morning, and thank you, Eric, and JPMorgan for the opportunity to provide an update on the momentum at Revolution Medicines and our conviction that we continue on target to outsmart cancer on behalf of patients with RAS-addicted cancers and to create shareholder value. Please review our notice regarding legal disclaimers. RAS proteins -- RAS mutations are among the most common genetic causes of human cancers despite accelerated approvals of 2 KRAS
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
